Case Study: Adela accelerates cancer detection and MRD diagnostics with Dendi LIS

Adela detects cancer recurrence up to 14.9 months earlier with Dendi

Adela, an innovator in blood testing for early cancer detection, faced the challenge of commercializing and delivering its novel Minimal Residual Disease (MRD) diagnostic test to patients and providers. To support this effort, the company partnered with vendor Dendi to implement its laboratory information system (LIS).

Dendi implemented a suite of tailored solutions for Adela, including seamless NGS pipeline integrations, robust APIs for data reconciliation, and enhanced security. The solution also featured custom report templates with advanced data visualization and faxing support for streamlined communication. This partnership equipped Adela to effectively deliver its clinically validated test, which had been shown to identify cancer recurrences up to 14.9 months earlier than standard methods.

Adela